Loading…
Lobbying Spend
—
Filings
8
Firms Hired
1
Active Period
2025–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
State of Men’s Health Act
2026 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Client expense: — · Firm income: $70,000
Matched citations: H.R. 7602
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Client expense: — · Firm income: $70,000
Matched citations: H.R. 8269
Financial Services and General Government Appropriations Act, 2027
2026 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Client expense: — · Firm income: $70,000
Matched citations: H.R. 8495
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
2026 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Client expense: — · Firm income: $70,000
Matched citations: H.R. 8646
Lower Costs, More Transparency Act of 2026
2026 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Client expense: — · Firm income: $70,000
Matched citations: H.R. 9393
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Client expense: — · Firm income: $70,000
Matched citations: S. 3788
State of Men’s Health Act
2026 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status, including Section 304 of H.R. 9393; issues related to consumer health care products supply chain; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646) and Financial Services and General Government Appropriations Act, 2027 (H.R. 8495); State of Men's Health Act (H.R. 7602, S. 5113); GRAS reform; CLEAR LABELS Act (S. 3788, H.R. 8269).
Client expense: — · Firm income: $70,000
Matched citations: S. 5113
Financial Services and General Government Appropriations Act, 2027
2026 · second_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status; Issues related to consumer health care products supply chain; Issues related to FY27 appropriations report language, including H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 and H.R. 8495 - Financial Services and General Government Appropriations Act, 2027.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 8495
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
2026 · second_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status; Issues related to consumer health care products supply chain; Issues related to FY27 appropriations report language, including H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 and H.R. 8495 - Financial Services and General Government Appropriations Act, 2027.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 8646
Over-the-Counter Monograph Drug User Fee Amendments
2026 · first_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 4273
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
2026 · first_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 5371
Over-the-Counter Monograph Drug User Fee Amendments
2026 · first_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Client expense: — · Firm income: $70,000
Matched citations: S. 2292
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
2026 · first_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to implementation of the OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371; Issues related to consumer health care products supply chain; Issues related to FY2027 appropriations report language.
Client expense: — · Firm income: $70,000
Matched citations: S. 2529
Over-the-Counter Monograph Drug User Fee Amendments
2025 · fourth_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4273
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
2025 · fourth_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5371
Over-the-Counter Monograph Drug User Fee Amendments
2025 · fourth_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Client expense: — · Firm income: $60,000
Matched citations: S. 2292
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
2025 · fourth_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments H.R. 4273/S. 2292; S. 2529 - The SMART OTC Act; Division F, Title V of The Continuing Appropriations and Extensions Act, 2026 - H.R. 5371.
Client expense: — · Firm income: $60,000
Matched citations: S. 2529
Over-the-Counter Monograph Drug User Fee Amendments
2025 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 4273
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
2025 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5371
Over-the-Counter Monograph Drug User Fee Amendments
2025 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Client expense: — · Firm income: $60,000
Matched citations: S. 2292
A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches.
2025 · third_quarter · Firm: AKIN GUMP STRAUSS HAUER FELD
Issues related to OTC Drug Monograph User Fee Program reauthorization and non-prescription drug status - The Over-the-Counter Monograph Drug User Fee Amendments (H.R. 4273/S. 2292); Issues related to S. 2529 - A bill to increase the clarity and predictability of the process for developing applications for Rx-to-nonprescription switches; Issues related to the Continuing Appropriations and Extensions Act, 2026 (H.R. 5371).
Client expense: — · Firm income: $60,000
Matched citations: S. 2529
Source: Senate LDA